Alimera Sciences, Inc. (NASDAQ:ALIM) insider Richard S. Eiswirth, Jr. sold 13,410 shares of the company’s stock in a transaction on Friday, January 19th. The stock was sold at an average price of $1.20, for a total value of $16,092.00. Following the transaction, the insider now directly owns 84,779 shares in the company, valued at $101,734.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of Alimera Sciences, Inc. (NASDAQ ALIM) traded down $0.04 during mid-day trading on Friday, hitting $1.20. The stock had a trading volume of 329,291 shares, compared to its average volume of 180,769. The company has a debt-to-equity ratio of -0.71, a quick ratio of 4.65 and a current ratio of 4.84. Alimera Sciences, Inc. has a 1-year low of $1.11 and a 1-year high of $1.72. The firm has a market capitalization of $82.98, a P/E ratio of -3.87 and a beta of 2.15.
Alimera Sciences (NASDAQ:ALIM) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01. sell-side analysts forecast that Alimera Sciences, Inc. will post -0.27 earnings per share for the current year.
A number of equities analysts have recently issued reports on ALIM shares. Zacks Investment Research raised Alimera Sciences from a “sell” rating to a “hold” rating in a research report on Monday, January 8th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Alimera Sciences in a research report on Wednesday, November 22nd. Cowen reaffirmed a “buy” rating on shares of Alimera Sciences in a research report on Thursday, November 2nd. Finally, ValuEngine downgraded Alimera Sciences from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Alimera Sciences currently has an average rating of “Hold” and a consensus price target of $3.38.
Alimera Sciences Company Profile
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.